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Abstract
Background: Melanoma is a highly metastatic type of cancer that is resistant to all standard anticancer therapies
and thus has a poor prognosis. Therefore, metastatic melanoma represents a significant clinical problem and
requires novel and effective targeted therapies. The protein kinase C (PKC) family comprises multiple isoforms of
serine/threonine kinases that possess distinct roles in cancer development and progression. In this study, we
determined whether inhibition of PKC could revert a major process required for melanoma progression and
metastasis; i.e. the E- to N-cadherin switch.
Methods: The cadherin switch was analyzed in different patient-derived primary tumors and their respective
metastatic melanoma cells to determine the appropriate cellular model (aggressive E-cadherin-negative/N-cadherin-
positive metastasis-derived melanoma cells). Next, PKC inhibition in two selected metastatic melanoma cell lines,
was performed by using either pharmacological inhibitors (Gö6976 and Gö6983) or stable lentiviral shRNA
transduction. The expression of E-cadherin and N-cadherin was determined by western blot. The consequences
of cadherin switch reversion were analyzed: cell morphology, intercellular interactions, and β-catenin subcellular
localization were analyzed by immunofluorescence labeling and confocal microscopy; cyclin D1 expression was
analyzed by western blot; cell metastatic potential was determined by anchorage-independent growth assay
using methylcellulose as semi-solid medium and cell migration potential by wound healing and transwell assays.
Results: Gö6976 but not Gö6983 reversed the E- to N-cadherin switch and as a consequence induced intercellular
interactions, profound morphological changes from elongated mesenchymal-like to cuboidal epithelial-like shape,
β-catenin translocation from the nucleus to the plasma membrane inhibiting its oncogenic function, and reverting
the metastatic potential of the aggressive melanoma cells. Comparison of the target spectrum of these inhibitors
indicated that these observations were not the consequence of the inhibition of conventional PKCs (cPKCs), but
allowed the identification of a novel serine/threonine kinase, i.e. protein kinase Cμ, also known as protein kinase
D1 (PKD1), whose specific inhibition allows the reversion of the metastatic phenotype in aggressive melanoma.
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Conclusion: In conclusion, our study suggests, for the first time, that while cPKCs don’t embody a pertinent
therapeutic target, inhibition of PKD1 represents a novel attractive approach for the treatment of metastatic
melanoma.
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Background
Melanoma is a highly metastatic and deadly type of cancer
that arises from melanocytes, melanin-producing cells res-
iding in the basal layer of the epidermis and necessary for
protection of skin cells from deleterious effects of ultravio-
let light. The incidence of melanoma is increasing very fast
worldwide [1]. When diagnosed early, most patients with
primary melanoma can be cured by surgical resection.
However, if not detected and removed early, melanoma
cells can metastasize rapidly. Metastatic melanoma has
historically been considered an untreatable disease, where
standard treatment options produced modest response
rates and failure to improve overall survival [2, 3]. Re-
cently, the treatment landscape for advanced melanoma
was revolutionized by the development of new targeted
and immune therapeutic strategies. Particularly, BRAF/
MAPK pathway inhibitors and immune checkpoint inhibi-
tors have proven to significantly improve survival in
melanoma patients in comparison to traditional therapeu-
tics [4, 5]. However, many patients develop resistance to
MAPK inhibitor therapies and most patients do not re-
spond to immunotherapies. Therefore, metastatic melan-
oma represents an important health problem and requires
novel and effective targeted therapies.
In human epidermis, normal melanocytes interact with
keratinocytes through the adhesion molecule E-cadherin.
This communication maintains differentiation state of
melanocytes and control their proliferation and migration
[6, 7]. Transformation of melanocytes into melanoma
entails a number of genetic and environmental factors
involving cell adhesion and growth regulatory genes.
One key event allowing melanoma progression is the
loss of E-cadherin and gain of another member of clas-
sical cadherins, i.e. N-cadherin [8, 9]. This cadherin switch
results in the loss of keratinocyte-mediated growth and
motility control [6] and enables melanoma cells to interact
directly with N-cadherin-expressing stromal cells from the
dermis, such as fibroblasts and vascular or lymphoid
endothelial cells [10]. These events are crucial to allow
melanoma cells to metastasize.
E- and N-cadherin are members of the classical cad-
herin family that play an important role in cell-cell
adhesion regulating morphogenesis during embryonic
development and maintaining integrity in developed tis-
sues [11]. These transmembrane glycoproteins mediate
calcium-dependent intercellular adhesion in a homophilic
manner. Cadherin-mediated cell-cell junctions are formed
as a result of interaction between extracellular domains of
identical cadherins, which are located on the membrane
of neighboring cells. The stability of these adhesive junc-
tions is insured by binding of the intracellular cadherin
domain with the actin cytoskeleton through the cytoplas-
mic proteins α-, β- and γ-catenins [12]. The E-cadherin is
expressed by most normal epithelial tissues and N-
cadherin is typically expressed by mesenchymal cells
which, in contrast to epithelial cells, are non-polarized,
elongated, less adherent between each other, motile and re-
sistant to anoikis [13]. However, many epithelium-derived
cancer cells have lost E-cadherin expression and inappro-
priately express N-cadherin. This cadherin switch has been
shown to promote tumor growth, motility and invasion
through a process called epithelial-mesenchymal transition
(EMT) [6, 14–16] and to be associated with metastasis and
poor prognosis in patients [17, 18]. Since functional restor-
ation of E-cadherin or depletion of N-cadherin in melan-
oma cells inhibits tumor cell growth, motility and invasion
in vitro and reduces tumorigenicity in vivo [6, 19], identifi-
cation of molecular mechanisms reverting the E- to N-
cadherin switch may be a way to identification of new po-
tential therapeutic targets for melanoma treatment.
The protein kinase C (PKC) family of serine/threonine
kinases includes multiple isozymes that are divided into
three groups, conventional, novel, or atypical, depending
on their requirements for Ca2+ or diacylglycerol for
activation [20]. Signaling through PKCs is induced by a
remarkable number of stimuli, including G-protein-
coupled receptor agonists and growth factors. Individual
PKC isozymes regulate a varied array of biological pro-
cesses including cell proliferation, survival, migration and
apoptosis. They are involved in the development and pro-
gression of different types of cancer including melanoma
[21, 22]. PKCu, also known as PKD1 (protein kinase D1)
was initially described as a member of the PKC family
[23]. However, PKD1 possesses distinct substrate specifi-
city [24] and has therefore recently been classified as a
novel subgroup of the calcium/calmodulin-dependent kin-
ase (CAMK) family [25]. Despite the new classification of
PKD1, this serine/threonine kinase shares with conven-
tional and novel PKCs common activators, such as phor-
bol esters [24], as well as potent inhibitors such as Gö6976
[26, 27]. Phorbol esters and Gö6976 inhibitor has been
shown to regulate cell junctions, cadherin expression and
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migration [28, 29]. However, to date, the role of PKCs in
cadherin switch and melanoma progression remains
unknown.
In the present study, we analyzed whether PKC inhib-
itors Gö6976 and Gö6983 would revert the E- to N-




The primary antibodies used were rabbit anti-E-cadherin,
rabbit anti-N-cadherin, mouse anti-β-catenin and rabbit
anti-PKD1 (1/500 for western blot and 1/50 for immuno-
fluorescence; Santa Cruz Biotechnology, Santa Cruz, CA),
goat anti-actin (1/200 for western blot; Santa Cruz
Biotechnology, Santa Cruz, CA) and rabbit anti-cyclin
D1 (1/1000 for western blot, Cell signaling technology,
Denvers, MA). Horseradish peroxidase-conjugated sec-
ondary antibodies used were goat anti-rabbit IgG (1/2000;
Dako, Glostrup, Denmark), rabbit anti-goat IgG (1/2000
Santa Cruz Biotechnology) and goat anti-mouse IgG
(1/5000; Rockland, Gilbertsville, PA). The Alexa Fluor-
conjugated secondary antibodies were Alexa-Fluor-594-
conjugated donkey anti-rabbit IgG, Alexa-Fluor-488-
conjugated donkey anti-mouse IgG conjugated (1/200;
Invitrogen, Cergy-Pontoise, France). Actin was stained
with Alexa-Fluor-488-conjugated phalloidin (1/50; Invi-
trogen, Cergy-Pontoise, France). The nucleus was stained
with 4',6-diamidino-2-phenylindole DAPI (1/50000; Invi-
trogen, Cergy-Pontoise, France). Gö6976 and Gö6983
were purchased from Calbiochem (Darmstadt, Germany).
All other biochemicals were from Sigma-Aldrich (St.
Louis, MO).
Cell culture
Primary (T1 and I5), their respective lymph-node metasta-
sis (G1 and M2), and the cutaneous metastasis (M4T2)
melanoma cell lines were obtained from 70-77-year old
patients from Institut Gustave Roussy (Villejuif, France),
as previously described [30]. These cells were cultured in
RPMI medium supplemented with 10% fetal bovine
serum (FBS), 100 units/mL penicillin and 100 μg/mL
streptomycin (P/S), and 1 mM sodium pyruvate (complete
medium).
Stable shRNA lentiviral transduction
For stable PKD1 depletion, cells were infected with human
PKCμ shRNA (sc-36245-v) or control shRNA (sc-108080)
lentiviral transduction particles from Santa Cruz Bio-
technology (Santa Cruz, CA) according to the manufac-
turer’s protocol. Stable clones expressing the shRNA
were selected with 2 μg/mL puromycin.
Western blot analysis
Cells were lysed for 20 min at 4 °C in 50 mM Tris–HCl
pH 7.4, 150 mM NaCl, 1 mM EDTA, 100 mM sodium
fluoride, 10 mM tetra-sodium diphosphate decahydrate,
2 mM sodium orthovanadate, 1 mM phenylmethylsulfo-
nylfluoride, 10 μg/mL aprotinin and 1% Nonidet P-40.
Lysates were clarified by centrifugation at 14,000 rpm for
10 min at 4 °C. 30–80 μg of total protein extracts were
separated by SDS-PAGE and transferred onto nitrocellu-
lose membranes. These were incubated with the specific
antibodies overnight at 4 °C and revealed by enhanced
chemiluminescence (Amersham, GE Healthcare, UK).
MTT assay
Cells were seeded in quadruplicates into 96-well plates
at a density of 1,000 cells per well in complete medium
and incubated for 1 to 6 days at 37 °C, 5% CO2. On the
day of analysis, cells were incubated with 0.5 mg/ml
MTT for 2 h at 37 °C. Then, 10% SDS were added to
each well and incubated for 16 h at 37 °C. Absorbance
value (OD) was measured at 570 nm.
Colony formation assay
Cells were resuspended in 2.5 mL of methylcellulose
(0.8%) prepared in complete medium containing vehicle
control (DMSO), 1 μM Gö6976 or 1 μM Gö6983. Cells
were then plated in uncoated 35 mm culture dishes and
incubated at 37 °C in a humidified atmosphere at 5%
CO2 for 3 weeks. Colonies were then photographed and
counted under a light microscope using a grid.
Wound healing assay
The scratch wound was created using 200 μL sterile pip-
ette tip in a confluent cell culture pre-treated for 24 h
with DMSO, 1 μM Gö6976 or 1 μM Gö6983. The
scratch area was washed and cells were re-incubated
with the same inhibitors. The images were taken at 0, 16
and 24 h. The lines show the area where the scratch
wound was created.
Transwell migration assay
24-well transwell chambers (Corning Costar, Corning,
NY, USA) with 8.0-μm pore size polycarbonate mem-
brane were used. 100,000 cells were plated in duplicates
in 200 μL serum-free RPMI medium in the upper well.
Complete medium was added to the lower well. After
24 h of incubation, cells that migrated through the
membrane to the lower well were all counted by light
microscopy.
Immunofluorescence
Cells cultured on cover glass slides (Menzel-Gläser;
Braunschweig, Germany) were fixed and permeabilized
with Cytofix-Cytoperm solution (BD Biosciences, Le Pont
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de Claix, France) for 10 min at room temperature. Cells
were washed with 2% glycine solution, then blocked
with blocking buffer containing 2% FBS and 0.5% sap-
onin in PBS for 30 min at 37 °C. Cells were incubated
with the primary antibodies, then with Alexa Fluor-
conjugated secondary antibodies or phalloidin for 1 h
at room temperature each. DAPI was added for 2–
3 min at room temperature. The slides were mounted
with Mowiol solution (Southern Biotech, Birmingham,
AL). Immunofluorescence images were acquired with
inverted epifluorescence or confocal microscopes and ana-
lyzed with IMSTAR or LEICA softwares, respectively.
Enzyme-linked immunosorbent assay (ELISA)
Soluble E-cadherin was detected in conditioned media
from shRNA lentiviral transduced cells with sandwich
ELISA (Human E-cadherin EIA Kit, Takara Bio, Osaka,
Japan), according to the manufacturer’s specifications.
Briefly, samples were added, in triplicates, to the wells
and then incubated in the dark for 2 h at 37 °C. The
wells were washed 3 times with TBS containing 0.1%
Tween-20 and 5 mM CaCl2. The antibody conjugated to
peroxidase and specific to human E-cadherin was added
for 1 h at 37 °C, the wells were washed 4 times and then
the substrate solution (TMBZ) was added for 15 min at
room temperature before the reaction was stopped with
1 N sulfuric acid. The plate was read at 450 nm.
Results
Comparative analysis of E- and N-cadherin expression
and oncogenic properties between primary melanoma
cells and their respective metastatic cells
To study the possibility to revert the E- to N-cadherin
switch and the tumor phenotype in metastatic melanoma,
the appropriate cellular model (i.e. aggressive metastasis-
derived melanoma cells that do not express E-cadherin
but strongly express N-cadherin) was first selected. There-
fore, the expression of these cadherins and the oncogenic
properties (i.e. anchorage-dependent and -independent
growth and migration) were analyzed in two couples of
primary and corresponding lymph-node metastasis mel-
anoma cells. I5 (primary tumor) and M2 (lymph-node
metastasis) cell lines were derived from the same patient.
T1 (primary tumor) and G1 (lymph-node metastasis) cell
lines were derived from another patient.
The expression of E- and N-cadherins in I5, M2, T1
and G1 melanoma cell lines was analyzed by western
blot (Fig. 1a). High expression levels of E-cadherin and
very low expression levels of N-cadherin were found in
T1 and G1 cells. On the other hand, both I5 and M2
cells were found to express N-cadherin but not E-
cadherin. Specifically, the metastatic M2 cells showed a
significant 5-fold increase in N-cadherin expression level
in comparison to their corresponding primary tumor cells
(I5). These results suggest that the I5 and M2 melanoma
cells arise from melanocyte(s) that underwent the cad-
herin switch.
The proliferation (Fig. 1b), anchorage-independent
growth (Fig. 1c) and migration (Fig. 1d) of the melanoma
cell lines were also analyzed. Except for the I5 cell line,
these mesenchymal features strongly and significantly cor-
relate with high N-cadherin and low E-cadherin expres-
sion in our set of melanoma models (Additional file 1).
Furthermore, significantly higher proliferation, anchorage-
independent growth (anoikis resistance) and migration
rates were found in M2 cells that don’t express E-cadherin
but express the highest level of N-cadherin compared to
I5, T1 and G1 cells. Thus, the M2 cell line is the most ag-
gressive among this set of melanoma models.
Taken together, these results suggest that the highly
aggressive E-cadherin-negative/N-cadherin-positive meta-
static M2 cell line is an appropriate cellular model to
study the possibility to induce the reversion of the cad-
herin switch and tumor phenotype in aggressive meta-
static melanoma.
Effect of Gö6976 and Gö6983 on E- and N-cadherin ex-
pression in M2 metastatic melanoma cells
To determine whether PKC inhibitors may affect the ex-
pression of E- and/or N-cadherin in metastatic melanoma
cells, M2 cells were incubated with 1 μM Gö6976 or 1 μM
Gö6983 for different periods of time (0, 1, 3, 24 and 48 h),
then analyzed by western blot (Fig. 2). Compared to un-
treated control cells (0 h), Gö6976-treated cells exhibited
an induced expression of E-cadherin and a significantly
decreased (by approximately 50%) expression of N-
cadherin as soon as 1 h and 3 h of treatment, respect-
ively. This Gö6976-induced N- to E-cadherin switch
was maintained for at least 48 h. However, treatment of
the M2 cells with Gö6983 affected neither N-cadherin
nor E-cadherin expression. These results demonstrate
that Gö6976 but not Gö6983 induces E-cadherin and
reduces N-cadherin expression in M2 metastatic mel-
anoma cells.
Effect of Gö6976 and Gö6983 on the morphology and
intercellular interactions of M2 metastatic melanoma cells
The cadherin switch is a major event of the EMT during
tumor progression that entails profound morphological
changes to a cell and affects intercellular interactions [16].
Therefore, the effect of the PKC inhibitors (Gö6976 and
Gö6983) on the M2 cell morphology and intercellular in-
teractions was analyzed by actin labeling and fluorescent
microscopy (Fig. 3a). Untreated cells (0 h) showed a typ-
ical elongated mesenchymal-like shape and formed very
few cell-cell contacts. Treatment with Gö6976 induced a
rapid cell shape change from elongated to cuboidal ac-
companied by a strong increase in cell-cell interactions
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(Fig. 3a). These changes were observed as early as 1 h after
treatment with Gö6976 and were maintained for at least
48 h. In contrast, Gö6983-treated cells remained elongated
and isolated (Fig. 3a). Thus, Gö6976 but not Gö6983 in-
duces a rapid cell shape modification from an elongated
mesenchymal-like structure into a “cuboidal” epithelial-like
Fig. 1 Comparative analysis of E- and N-cadherin expression and oncogenic properties between primary tumor and respective metastatic melanoma
cell lines a. Protein extracts from the primary tumor (I5 and T1) and respective lymph-node metastatic (M2 and G1) melanoma cell lines were analyzed
by western blot using anti-E-cadherin, anti-N-cadherin and anti-actin antibodies. The results presented are those of typical experiments. b. The
proliferation of I5, M2, T1 and G1 cells was analyzed over six days by MTT assay. Results presented are the means ± SD for three independent
experiments. c. I5, M2, T1 and G1 cells were cultured in methylcellulose semi-solid medium for three weeks. Then, the colonies formed were
counted. The results are presented as the percentage of seeded cells that form colonies (clonogenicity) and are the means ± SD for three
independent experiments. ***, p < 0.005 versus respective primary tumor cells. d. Representative images of cell migration evaluated by wound
healing assay. Images of wound repair were taken at 0 and 24 h after wound
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shape and a strong increase in intercellular interactions in
M2 metastatic melanoma cells.
Cellular localization of the Gö6976-induced E-cadherin
molecules
Since Gö6976 was found to regulate the expression of
the cell adhesion molecules N- and E-cadherins as well
as the intercellular interactions of M2 cells (Figs. 2 and
3a), the subcellular localization of these cadherins was
next analyzed. Therefore, M2 cells were treated with
Gö6976 or Gö6983 for 24 h before actin and N-
cadherin (Fig. 3b) or E-cadherin (Fig. 3c) fluorescent
co-staining and confocal microscopy analysis. Whatever
the condition, N-cadherin staining was mostly localized
in the cytoplasm (Fig. 3b). On the other hand, E-
cadherin staining was observed only in Gö6976-treated,
but not in untreated or Gö6983-treated cells and was
strongly increased at the cell-cell contacts (Fig. 3c).
Thus, Gö6976-incited cell clustering is associated with
induced E-cadherin expression and localization at the
intercellular interactions.
Effect of Gö6976 and Gö6983 on the subcellular
localization of β-catenin
The stability of E-cadherin-mediated intercellular inter-
actions requires the accumulation of β-catenin at the
plasma membrane at these cell-cell contact sites [31].
Loss of E-cadherin expression during EMT and tumor
progression is accompanied by β-catenin translocation
to the nucleus where it acts as oncogenic transcription
factor [32, 33]. Since Gö6976-treatment induces the ex-
pression of E-cadherin at the cellular junctions in the E-
cadherin-negative metastatic melanoma cells (M2 cells),
the status of β-catenin in these cells and the effect of
the PKC inhibitors (Gö6976 and Gö6983) on its subcel-
lular localization and expression were determined
(Fig. 4a and b). In untreated M2 mesenchymal-like mel-
anoma cells (0 h), β-catenin was accumulated at high
levels in the nuclei of the cells in addition to its loca-
tion at the plasma membrane (Fig. 4a). When the cells
were treated with Gö6976, β-catenin staining disap-
peared from the nuclei as soon as 1 h of treatment and
was observed at the plasma membrane (Fig. 4a, left
column). This Gö6976-induced relocation of β-catenin
Fig. 2 Gö6976 but not Gö6983 inhibits N-cadherin expression and induces E-cadherin expression in M2 metastatic melanoma cells. M2 metastatic
melanoma cells were seeded in 6-well plates at the density of 25,000 cells per well. After three to five days of culture, cells were treated with
1 μM Gö6976 or 1 μM Gö6983 for different periods of time (0, 1, 3, 24 or 48 h). Cells were then lysed and proteins analyzed by western blot using
anti-E-cadherin, anti-N-cadherin or anti-actin antibodies. The autoradiograms presented are those of a typical experiment. The histogram represents
quantitative analysis of N-cadherin expression normalized to untreated control cells (0 h). The results presented are the means ± SD for three
independent experiments. **, p < 0.01 versus untreated cells
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Fig. 3 Gö6976 but not Gö6983 induces rapid cell shape modification and E-cadherin-associated cell-cell interactions in M2 mesenchymal-like
metastatic melanoma cells. M2 metastatic melanoma cells were seeded in 6-well plates at the density of 12,500 cells per well. After three to five
days of culture, cells were treated with 1 μM Gö6976, 1 μM Gö6983 or vehicle (DMSO) for different periods of time (0, 1, 3, 24 or 48 h) (a) or for
24 h only (b and c). Cells were then fixed, permeabilized and stained for actin (green) alone (a), co-stained for actin and N-cadherin (red) (b) or
co-stained for actin and E-cadherin (red) (c). Isotype-matched control antibodies were used. Cell nuclei were stained with DAPI (blue). Cells were
analyzed under epifluorescence (a) or confocal (b and c) microscope. Images are representative fields from three or more independent experiments
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from the nucleus to the plasma membrane was stable
and maintained for at least 48 h of treatment (Fig. 4a,
left column). Noteworthy, Gö6976 did not affect β-
catenin expression (Fig. 4b). On the other hand, when
the cells were treated with Gö6983, β-catenin was still
located at high levels in the nuclei of the cells whatever
the duration of treatment (1–48 h) (Fig. 4a, right col-
umn). In conclusion, Gö6976, but not Gö6983, induces
the translocation of β-catenin from the nucleus to the
plasma membrane.
Fig. 4 Gö6976 but not Gö6983 induces rapid β-catenin translocation outside of the nucleus and reduces cyclin D1 expression in M2 metastatic
melanoma cells. M2 metastatic melanoma cells were seeded in 6-well plates at the density of 12,500 cells per well. After three to five days of
culture, cells were treated with 1 μM Gö6976 or 1 μM Gö6983 for different periods of time (0, 1, 3, 8, 24 or 48 h). a. After treatment, cells were
fixed, permeabilized, stained for β-catenin (green) and analyzed under a confocal microscope. Isotype-matched control antibody and DAPI (blue)
were used. Images are representative fields from three or more independent experiments. b. After treatment cells were lysed and proteins
analyzed by western blot using anti-β-catenin or anti-actin antibodies. The autoradiograms presented are those of a typical experiment. c. After
treatment cells were lysed and proteins analyzed by western blot using anti-cyclin D1 or anti-actin antibodies. The autoradiograms presented are
those of a typical experiment. The histogram represent quantitative analysis of cyclin D1 expression following Gö6976 treatment normalized to untreated
control cells (0 h). The results presented are the means ± SD for three independent experiments. **, p< 0.01; ****, p< 0.0001 versus untreated cells
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Effect of Gö6976 on cyclin D1 expression
To determine whether the Gö6976-induced relocation of
β-catenin from the nucleus to the plasma membrane
was associated with a decrease in its oncogenic function,
the effect of Gö6976 treatment on the expression of a
major β-catenin target, i.e. the oncoprotein cyclin D1,
was analyzed (Fig. 4c). M2 cells were incubated with
Gö6976 or Gö6983 for different periods of time then
lysed and cyclin D1 expression analyzed by western blot
using a specific antibody. As shown in Fig. 4a, cyclin D1
was strongly expressed in untreated M2 cells (0 h).
Gö6976 treatment markedly inhibited cyclin D1 expres-
sion levels over time; by approximately 41% and 93%
after 8 and 48 h of treatment, respectively. Thus,
Gö6976 treatment inhibits cyclin D1 expression in M2
melanoma cells. In contrast to Gö6976, Gö6983 didn’t
have any significant effect on cyclin D1 expression.
These data further confirm that the reduction in cyclin
D1 by Gö6976 may reflect changes in cadherin expres-
sion patterns.
Effect of Gö6976 and Gö6983 on the metastatic and
migration potential of M2 melanoma cells
Loss of E-cadherin expression, nuclear localization of
β-catenin and cyclin D1 expression are characteristics
that have been shown to correlate with transformation,
increased oncogenic activity and progression of most
cancers, including melanoma [9, 34]. To test whether
the Gö6976-induced reversion of these characteristics
(Figs. 1, 2, 3 and 4) correlates with a reduced aggressiv-
ity of the metastatic melanoma cells, the effect of this in-
hibitor on the anchorage-independent growth (reflecting
cell metastatic potential) and migration capacity of the
M2 cells was determined (Fig. 5).
Anchorage-independent growth was analyzed by study-
ing the ability of M2 cells treated or not with Gö6976 or
Gö6983 to survive, grow and form colonies in the methyl-
cellulose semi-solid medium. As shown in Fig. 5a, Gö6976
strongly reduced the number and volume of the colonies
formed in methylcellulose (by 54% and 93.2% respect-
ively), whereas Gö6983 had no significant effect. Gö6976
also strongly inhibited by 62.9% (Fig. 5b) and 91.9%
(Fig. 5c) the horizontal (wound healing assay) and chemo-
tactic (transwell assay) migrations, respectively.
Noteworthy, although the horizontal migration was
not affected by Gö6983 (Fig. 5b), this inhibitor signifi-
cantly reduced, by 50%, the chemotactic migration of
M2 cells but to a lesser extent than Gö6976 (percentage
of inhibition = 93.2%) (Fig. 5c).
Together, these results indicate that the Gö6976-
induced E-cadherin expression, membrane translocation
of β-catenin and loss of cyclin D1 expression correlate
with a decreased anchorage-independent growth and mi-
gration capacity of the M2 metastatic melanoma cells.
Effect of Gö6976 and Gö6983 on the metastatic and
migration potential of M4T2 melanoma cells
To further confirm the ability of Gö6976 to revert the E-
to N-cadherin switch and pro-metastatic phenotype of
aggressive melanoma cells, the effect of this inhibitor
was also tested on M4T2 cells that are derived from the
cutaneous metastasis of a different melanoma patient
and express high levels of N-cadherin but low levels of
E-cadherin.
As shown in Fig. 6, treatment of M4T2 melanoma cells
with Gö6976 strongly inhibits anchorage-independent
growth (approximately 76.9% and 97.1% reduction in the
number and volume of colonies, respectively; Fig. 6a),
horizontal migration (very faint wound closure 24 h after
scratch while full closure observed after at least 16 h for
control DMSO-treated cells; Fig. 6b) and chemotactic mi-
gration (by approximately 92%; Fig. 6c).
Furthermore, treatment of M4T2 cells with Gö6976
also induced a 4.7-fold increase in E-cadherin expression
and a decrease in N-cadherin expression by 40.8%
(Fig. 6d) compared to control (DMSO-treated) cells.
On the other hand, treatment of M4T2 cells with
Gö6983 reduced their chemotactic migration by only
33.6% (vs. 92% when treated with Gö6976) (Fig. 6c), and
did not affect horizontal migration (Fig. 6b), anchorage-
independent growth (Fig. 6a) or cadherin switch (Fig. 6d).
Together, these results show that in the same way as
in M2 cells, treatment with Gö6976, but not with
Gö6983, induces N- to E-cadherin switch and reversion
of the pro-metastatic phenotype in the M4T2 metastatic
melanoma cells.
In contrast to the metastatic melanoma cells (M2 and
M4T2 cell lines) (Figs. 2, 5a and 6a, d), Gö6976 inhibitor
did not significantly affect the expression of E- or N-
cadherins or the anchorage-independent growth in the
primary melanoma cell line (I5) (Additional file 2). Thus,
the effects of this inhibitor seem to be specific to advanced
metastatic melanoma.
Taken all together, our results have shown that the
PKC inhibitors; i.e. Gö6976 and Gö6983, differentially
affect the reversion of E- to N-cadherin switch and
metastatic phenotype in aggressive melanoma cells
(Figs. 1, 2, 3, 4, 5 and 6). In fact, whereas Gö6976 in-
duces E-cadherin expression, β-catenin translocation
from the nucleus to the plasma membrane and intercel-
lular interactions, and inhibits N-cadherin and cyclin
D1 expression, anchorage-independent growth and
horizontal and chemotactic migration of metastatic
mesenchymal-like melanoma cells, Gö6983 could only
reduce the chemotactic migration but to a much lesser
extent than Gö6976. These results suggest that a spe-
cific PKC isoform targeted by Gö6976 but not by
Gö6983 would be involved in the reversion of the cad-
herin switch and metastatic phenotype and; therefore,
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Fig. 5 Gö6976 but not Gö6983 strongly inhibits anchorage-independent growth and migration of M2 metastatic melanoma cells. a. M2 metastatic
melanoma cells were seeded in methylcellulose (400 cells per plate) containing 1 μM Gö6976 or 1 μM Gö6983. After three weeks of culture, the
colonies were counted, photographed and their volume determined. The quantifications presented are the means ± SD for three independent
experiments. **, p < 0.01; ***, p < 0.001 versus control DMSO treated cells. b. Scratch wounds were created by scraping confluent monolayers
of M2 cells, pre-treated one day before with 1 μM Gö6976, 1 μM Gö6983 or DMSO. After 24 h, cell migration from the wound edges into the
wounded area was evaluated. Cells were photographed at 0 and 24 h after wound. The photographs presented are those of a representative
experiment. Values presented under each photograph represent the mean ± SD of numbers of cells that migrated into the wound for three
independent experiments. c. Cells were incubated in RPMI medium containing 1 μM Gö6976, 1 μM Gö6983 or DMSO in the upper well of a
transwell chamber while in the lower well RPMI medium supplemented with 10% FBS was added. After 24 h, cells that invaded to the lower
well were counted. The results presented are the means ± SD for three independent experiments. *, p < 0.05; ****, p < 0.0001 versus control
DMSO treated cells
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Fig. 6 Gö6976 but not Gö6983 strongly inhibits anchorage-independent growth and migration and reverses the E to N-cadherin switch in M4T2 meta-
static melanoma cells. a. M4T2 metastatic melanoma cells were seeded in methylcellulose (1000 cells per plate) containing 1 μM Gö6976 or 1 μM Gö6983.
After three weeks of culture, the colonies were counted, photographed and their volume determined. The quantifications presented are the means ± SD
for three independent experiments. ****, p< 0.0001 versus control DMSO treated cells. b. Scratch wounds were created by scraping confluent monolayers
of M4T2 cells, pre-treated one day before with 1 μM Gö6976, 1 μM Gö6983 or DMSO. After 16 and 24 h, cell migration from the wound edges into the
wounded area was evaluated. Cells were photographed at 0, 16 and 24 h after wound. The photographs presented are those of a representative
experiment. c. Cells were incubated in RPMI medium containing 1 μM Gö6976, 1 μM Gö6983 or DMSO in the upper well of a transwell chamber while
in the lower well RPMI medium supplemented with 10% FBS was added. After 24 h, cells that invaded to the lower well were counted. The results
presented are the means ± SD for three independent experiments. *, p < 0.05; **, p < 0.01 versus control DMSO treated cells. d. Cells were seeded
in 6-well plates at the density of 25,000 cells per well. After three to five days of culture, cells were treated with 1 μM Gö6976, 1 μM Gö6983 or DMSO for
24 h). Cells were then lysed and proteins analyzed by western blot using anti-E-cadherin, anti-N-cadherin or anti-actin antibodies. The autoradiograms
presented are those of a typical experiment. The histograms represent quantitative analysis of E- or N-cadherin expression normalized to control DMSO
treated cells. The results presented are the means ± SD for two independent experiments. **, p< 0.01; ****, p< 0.0001 versus DMSO treated cells
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would become a pharmaceutical target for the treat-
ment of melanoma. Next, we searched to determine
this target.
Analysis of PKD1 expression in different melanoma cell
lines and correlation with E-/N-cadherin expression
Since Gö6976 is a selective inhibitor of PKCα, PKCβ and
PKCμ and Gö6983 a selective inhibitor of PKCα and
PKCβ but not PKCμ [26, 27], we hypothesized that the
specific inhibition of PKCμ, which is also known as
PKD1 (protein kinase D1), would be responsible for the
Gö6976-induced N- to E-cadherin switch and tumor re-
version in metastatic melanoma cells.
To test this hypothesis, first, the expression of PKD1
and its relationship with E- and N-cadherin statuses were
analyzed by western blot in different melanoma cell lines
(i.e. T1, G1, I5, M2 and M4T2) (Fig. 7). In T1 and G1 mel-
anoma cells that express high levels of E-cadherin but very
low levels of N-cadherin, PKD1 expression was very faint
(Fig. 7a). In I5, M2 and M4T2 melanoma cells, that ex-
press null or very low levels of E-cadherin but high levels
of N-cadherin, PKD1 expression was strong with maximal
expression in the most aggressive cell line (i.e. M2 cells)
(Fig. 7a). In addition to this strong qualitative correlation
between PKD1 expression and E-cadherin negative/N-
cadherin positive phenotype, quantitative correlation was
also confirmed by Spearman correlation coefficient ana-
lysis (r = 0.921; p = 0.006 and r = −0.8; 0.067 for correlation
with N-cadherin and E-cadherin, respectively) (Fig. 7b).
Furthermore, PKD1 expression significantly correlated
with the mesenchymal features of the melanoma cell lines
used in this study and was associated with a high meta-
static potential (anchorage-independent growth and mi-
gration) (Additional file 3).
These data support the hypothesis that the effect of
Gö6976 on N- to E-cadherin switch and tumor reversion
in melanoma cells would be due to the inhibition of
PKD1.
PKD1 silencing by lentiviral vector based shRNA
transduction in the M2 metastatic melanoma cells
Next, to allow direct analysis of the role of PKD1 inhib-
ition in human metastatic melanoma, M2 cell clones sta-
bly expressing shRNAs directed against PKD1 (named P2,
P3, P4, P5, P6 and P7) or scrambled shRNA control
(named C1 and C2) were generated by lentiviral particles
transduction. The efficiency of PKD1 knockdown was de-
termined by western blot (Fig. 8). The results show that
whereas the clones transduced with lentiviral control
shRNA express similar levels of PKD1 protein as parental
M2 cells, clones transduced with lentiviral PKD1-specific
shRNAs show varying degrees of PKD1 knockdown effi-
ciency. PKD1 expression was strongly inhibited in P6, P2,
P7, P3 and P4 clones by approximately 90.9, 90.78, 88.1,
68.7 and 63.5%, respectively, but weakly inhibited in P5
clone by approximately 20%.
Effect of PKD1 depletion on E-cadherin expression in M2
mesenchymal-like melanoma cells
Since Gö6976 but not Gö6983 induces E-cadherin ex-
pression in the E-cadherin-negative metastatic melan-
oma cells (Fig. 2), we tested whether PKD1 depletion
would have the same effect. Therefore, total proteins
from lentiviral control (C1 and C2) and PKD1-specific
(P2, P3, P4, P5 and P6) shRNA-transduced M2 clones
cultured in semi-solid methylcellulose medium (Fig. 9a)
or in adherent conditions (Fig. 9b) were extracted and
analyzed for PKD1 and/or E-cadherin expression by
western blot. A very faint protein band at 120 kDa and a
very thick band at 80 kDa representing full-length and
cleaved E-cadherin molecules, respectively, were ob-
served in the protein extracts from PKD1-depleted (P2,
P3, P4 and P6) M2 clones cultured in methylcellulose
but not from control (C1 and C2) or PKD1-faintly inhib-
ited (P5) M2 clones (Fig. 9a). Nonetheless, when these
cells were cultured under adherent conditions (Fig. 9b),
neither full-length nor cleaved E-cadherin corresponding
bands could be observed in the protein extracts from
any of the M2 clones (Fig. 9b).
Since a strong expression of cleaved E-cadherin was ob-
served in PKD1-depleted M2 clones cultured in methylcel-
lulose, we asked whether induced E-cadherin would be
cleaved and secreted in the medium of the adherent cells
while sequestered in the spheres of colonies formed in
methylcellulose. To test this hypothesis, conditioned media
from control (C1 and C2) and PKD1-specific (P3, P4, P5
and P6) shRNA-transduced M2 clones were analyzed for
the presence of soluble E-cadherin by ELISA. As indicated
in Fig. 9c, significant amounts of soluble E-cadherin were
detected in the media of PKD1-specific (P3, P4, P5 and P6)
but not control (C1 and C2) shRNA-transduced M2
clones. Taken together, these results indicate that PKD1
depletion induces the expression of E-cadherin that is
cleaved and secreted in M2 cells.
Interestingly, PKD1 knockdown also induced the ex-
pression of E-cadherin in M4T2 metastatic melanoma
cells. However, in contrast to the M2 cells, full-length E-
cadherin was detected in M4T2 cells (Additional file 4).
This result further confirms the role of PKD1 in the
regulation of E-cadherin expression and also suggests
that the mechanism leading to the cleavage of the newly
formed E-cadherin molecules in M2 cells is cell-context
specific.
Effect of PKD1 depletion on the cell shape and cell-cell
interactions in M2 melanoma cells
Since Gö6976 but not Gö6983 induces a rapid cell shape
modification (from elongated to cuboidal) and cell-cell
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interactions in M2 cells (Fig. 3a), we tested whether
PKD1 depletion may exert the same effect. Therefore,
the cell morphology and intercellular interactions of
control (C1 and C2) and PKD1-specific (P2, P3, P4, P5,
P6 and P7) shRNA-transduced M2 clones were analyzed
by actin-labeling and confocal microscopy (Fig. 10).
Results showed that all shRNA-transduced M2 clones
(control and PKD1-depleted) present typical elongated
Fig. 7 Protein kinase D1 expression positively correlates with N-cadherin and negatively correlates with E-cadherin in primary and metastatic
melanoma cells. Protein extracts from primary (T1 and I5) and metastatic (G1, M2 and M4T2) melanoma cells were analyzed by western blot
using anti-PKD1, anti-E-cadherin, anti-N-cadherin and anti-actin antibodies. a. The results presented are those of typical experiments. The histograms
represent quantitative analysis of PKD1, N-cadherin and E-cadherin expression from two independent experiments. b. The table represents the
relationship between PKD1 protein levels and E-cadherin and N-cadherin levels in the melanoma cell lines
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mesenchymal-like shape and form very few cell-cell
contacts, suggesting that PKD1 depletion could induce
neither reversion of mesenchymal-like morphology nor
intercellular interactions in M2 cells.
Effect of PKD1 silencing on the metastatic potential of M2
melanoma cells
To determine whether PKD1 inhibition may affect the
metastatic potential of M2 melanoma cells, control
(C1 and C2) and PKD1-specific (P2, P3, P4, P5, P6 and
P7) shRNA-transduced M2 clones were assayed for an-
chorage-independent growth and migration. Results show
that anchorage-independent growth of PKD1-depleted
(i.e. P2, P3, P4, P6 and P7) M2 clones was strongly inhib-
ited by 77.5, 74.1, 97.8, 78 and 54.5%, respectively, in com-
parison to control shRNA-transduced (C1 and C2) and
parental (M2) cells (Fig. 11a). Furthermore, except for P4
clone, chemotactic migration of all other PKD1-depleted
(P2, P3, P6, P7) M2 clones was strongly inhibited by 80.4,
73.6, 93.7 and 84%, respectively (Fig. 11b). However, hori-
zontal (wound healing) migration was not significantly
(P4) or weakly inhibited by 27% (P3), 33% (P6) and 35%
(P7) compared to control shRNA-transduced (C1 and C2)
cells, in all PKD1-depleted clones, except for P2 clone
(strong inhibition by 70.5%) (Fig. 11c).
Anchorage-independent growth and migration rates of
P5 clone, in which PKD1 expression was only slightly
inhibited, were similar to control cells (Fig. 11) suggest-
ing that a specific and strong PKD1 inhibition is re-
quired to revert the metastatic phenotype in melanoma
cells.
Discussion
In this study, we tested whether PKC inhibitors (such as
Gö6976 and Gö6983) would revert the E- to N-cadherin
switch, a major hallmark of the EMT process, required
for melanoma progression and metastasis [9, 15, 35].
First, we analyzed the cadherin switch in two couples
of patient-derived primary (I5, T1) and their respective
lymph-node metastasis (M2, G1) melanoma cells. Differ-
ent profiles of E- and N-cadherin expression were
observed. When comparing T1 (primary tumor) and G1
(corresponding lymph node metastasis) melanoma cells,
both cell lines expressed high levels of E-cadherin and
very low levels of N-cadherin. Although these findings
are inconsistent with the theory of E- to N-cadherin
switch during melanoma progression (i.e. E-cadherin
expression in primary tumor and N-cadherin expression
in metastasis), the expression of E-cadherin by the
metastasis-derived cells (G1) might be the consequence
of a MET (mesenchymal-epithelial transition) that would
have occurred at the metastatic site. MET was postulated
to be part of the process of metastatic tumor formation
[36, 37]. In fact, progression of solid tumors involves
spatial and temporal occurrences of EMT, whereby tumor
cells acquire a more invasive and metastatic phenotype
[38]. Subsequently, the disseminated mesenchymal
tumor cells undergo the reverse transition, MET, at the
site of metastases, as metastases recapitulate the path-
ology of their corresponding primary tumors [39]. Just
as a critical EMT event is the downregulation or silen-
cing of E-cadherin and upregulation of N-cadherin, the
re-expression of E-cadherin and loss of N-cadherin is
proposed to be the important hallmark of MET [39].
Presently, it is unclear how MET facilitates the forma-
tion of metastases. Some findings suggest a possible
mechanism whereby MET helps the tumor cells to con-
struct connections with the resident non-neoplastic
epithelial cells and may enable dormancy and survival
of tumor cells at a lower metabolic load at target organ
Fig. 8 PKD1 silencing by lentiviral vector based shRNA transduction
in the M2 metastatic melanoma cells. Protein extracts from parental
(M2), lentiviral PKD1-specific (clones P2, P3, P4, P5, P6 and P7) and
control (clones C1 and C2) shRNA-transduced M2 cells were analyzed
by western blot using anti-PKD1 and anti-actin antibodies. The results
presented are those of typical experiments. The histograms represent
quantitative analysis of PKD1 expression normalized to C1 control
clone. The results presented are the means ± SD for two independent
experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001
versus C1 and C2 control clones
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Fig. 9 The E-cadherin induced by PKD1 depletion is cleaved in M2 metastatic melanoma cells. a. Protein extracts from control (C1 and C2 clones)
and PKD1 depleted (P2, P3, P4, P5, P6 and P7 clones) M2 cells cultured in methylcellulose semi-solid medium for three weeks were analyzed by
western blot using anti-PKD1, anti-E-cadherin and anti-actin antibodies. The results presented are those of typical experiments. b. Protein extracts
from control (C1 and C2 clones) and PKD1 depleted (P2, P3, P4, P5, P6 and P7 clones) M2 cells cultured in adherent conditions were analyzed by
western blot using anti-E-cadherin and anti-actin antibodies. T1 melanoma cells were used as positive control for E-cadherin expression. The results
presented are those of typical experiments. c. Conditioned media from control (C1 and C2) and PKD1 depleted (P3, P4, P5 and P6) M2 cells were
analyzed for E-cadherin by ELISA
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[39]. Consistently, G1 cells, that may be derived from
metastatic cells that have underwent MET, grow very
slowly, are non-tumorigenic and do not migrate. On
the other hand, E-cadherin expression was absent in
both I5 (primary tumor) and M2 (corresponding lymph
node metastasis) melanoma cells while N-cadherin ex-
pression was significantly higher in the metastasis cells,
suggesting that I5 primary tumor cells may have already
underwent EMT. However, these cells did not show
higher proliferation and migration potentials than their
counterparts T1 cells but progressed to highly aggres-
sive metastatic cells (i.e. M2 cells). This observation
suggests that depending on the cellular context, the
pro-metastatic effect of cadherin switch might require
additional events that could occur later in tumorigenesis
[16]. In agreement with this hypothesis, a study by Chen
et al. 2014 shows that E-cadherin loss in non-malignant
breast cells is insufficient to induce EMT or to enhance
their transforming potential [40]. Furthermore, other stud-
ies by Knudsen et al. 2005 show that N-cadherin expres-
sion in the mammary gland of transgenic mice (mice
expressing N-cadherin under the control of mouse mam-
mary tumor virus promoter) does not induce tumors.
Interestingly, even crossing these mice with mice express-
ing the Neu oncogene in the mammary gland does not
produce tumors more aggressive than those in mice ex-
pressing Neu alone [41]. However, crossing them with
mice expressing polyoma virus middle T antigen in the
mammary epithelium leads to increased metastasis [42].
These studies suggest that the effects of cadherin switch-
ing are late events in tumorigenesis and demonstrate that
the influence of an inappropriate cadherin on the pheno-
type of the cell is context dependent [16]. This could be
the same in melanoma cells. Thus, despite the E- to N-
cadherin switch in I5 primary melanoma cells, these cells
require additional mutations or events to acquire en-
hanced mesenchymal features allowing their invasion and
metastasis formation. The primary (I5) and corresponding
metastasis (M2) melanoma cells could be a good model to
study the events that are required in addition to the E- to
N-cadherin switch to allow melanoma progression to
metastatic phenotype. Interestingly, except for I5, cell lines
that express high N-cadherin and low E-cadherin levels
had a better capacity of proliferation, clonogenicity and
migration than cell lines with low N-cadherin and high E-
cadherin expression. Thus, consistent with the cadherin
switch theory in melanoma progression, our data show a
strong link between high N-cadherin/low E-cadherin
expression and tumor aggressiveness and defines M2
metastatic melanoma cells (Absent E-cadherin/high N-
cadherin expression and highly tumorigenic and motile)
as a pertinent model to study the possibility to revert the
E- to N-cadherin switch and the metastasis phenotype. In
addition to this lymph-node metastasis melanoma model,
another cutaneous metastasis melanoma model with low
E-cadherin/high N-cadherin expression (i.e. M4T2 cells)
was used to further confirm our results.
Treatment of metastatic melanoma cells with PKC in-
hibitors Gö6976 or Gö6983 resulted in different responses
regarding cadherin switch and oncogenic activity of these
cells. Gö6976 but not Gö6983 treatment induced the
expression of E-cadherin and inhibited the expression of
Fig. 10 PKD1 depletion does not affect the cell shape or cell-cell interactions in M2 mesenchymal-like metastatic melanoma cells. M2 melanoma
cells were seeded in 6-well plates at the density of 12,500 (control C1, C2 and P5 clones) or 25,000 (PKD1-depleted P2, P3, P4 and P6 clones) cells
per well. After three to five days of culture, cells were fixed, permeabilized and stained for actin (green). Cells were then analyzed under a confocal
microscope. Images are representative fields from three independent experiments
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N-cadherin in metastatic melanoma cells. This Gö6976-
induced N- to E-cadherin switch was associated with rapid
phenotypic and molecular changes that comply with the
generally described model of cadherin switch during
tumor progression [6, 14–16]. In fact, our results showed
that the Gö6976-induced E-cadherin expression and N-
cadherin loss were associated with a rapid cell shape
modification from an elongated mesenchymal-like struc-
ture into a ‘cuboidal’ epithelial-like shape and a strong
increase in cell-cell junctions [43–45]. Furthermore, treat-
ment of lymph-node metastatic melanoma cells with
Gö6976 induced the translocation of β-catenin from the
nucleus to the plasma membrane. However, the mem-
brane β-catenin staining in Gö6976-treated cells is not
perfectly lining the plasma membrane. In fact, it has been
shown that newly synthesized E-cadherin arrives at the
plasma membrane already in complex with β-catenin
[46–48]. Then, once at the plasma membrane, this β-
catenin pool is transferred to E-cadherins that were
already present at the plasma membrane. Furthermore,
the β-catenin released from E-cadherin may participate
in new exchange cycles [47]. Thus, since during the
times of Gö6976-treatment used in our present study
(0–48 h), E-cadherin expression is continuing to in-
crease (Fig. 2), so new E-cadherin molecules are still
being synthesized and transported to the plasma mem-
brane, the diffuse β-catenin staining may be explained
by these β-catenin-E-cadherin exchange cycles [47]. In
agreement with this hypothesis, in Gö6976-treated
cells, β-catenin staining, which completely disappeared
Fig. 11 PKD1 depletion inhibits anchorage-independent growth and migration of M2 metastatic melanoma cells. a. PKD1 depleted (P2, P3, P4,
P5, P6 and P7 clones) and control (C1 and C2 clones) M2 cells were cultured in methylcellulose semi-solid medium for three weeks. Then, the
colonies formed were counted. The quantifications presented are the means ± SD for three independent experiments. **, p < 0.01; ****, p < 0.0001
versus C1 and C2 control cells. b. Cells were incubated in RPMI medium in the upper well of a transwell chamber while in the lower well RPMI
medium supplemented with 10% FBS was added. After 24 h, cells that invaded to the lower well were counted. The results presented are the
means ± SD for three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus C1 and C2 control cells. c. Representative images of
cell migration evaluated by wound healing assay. Images of wound repair were taken at 0 and 24 h after wound and the cells that migrated to
the wounded area were counted. The results presented are the means ± SD for three independent experiments. *, p < 0.05; **, p < 0.01 versus C1
and C2 control cells
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from the nucleus, is mostly accumulated at the newly
formed intercellular junctions while less β-catenin staining
is observed at the free borders of the plasma membrane
or in the cytoplasm, consistent with E-cadherin staining
(Fig. 3c). This translocation of the β-catenin from the nu-
cleus to the plasma membrane favors its tumor suppressor
role of insuring the stability of E-cadherin-mediated inter-
cellular interactions to its oncogenic role of transcription
factor [32, 33], as further supported by the inhibition of
the expression of its target cyclin D1 after Gö6976 treat-
ment. These observations also suggest that the Gö6976-
induced E-cadherin molecules are functional. In addition
to these molecular changes, Gö6976 treatment resulted in
decreased anchorage-independent growth and motility of
metastatic melanoma cells, confirming the reversion of
the metastatic phenotype. In contrast to the metastatic
melanoma cells (M2 and M4T2 cell lines), Gö6976 inhibi-
tor did not significantly affect the expression of E- or N-
cadherins or the anchorage-independent growth in the
primary melanoma cell line (I5) (Additional file 2). Thus,
the effects of this inhibitor seem to be specific to advanced
metastatic melanoma suggesting that the reversion of the
mesenchymal features by Gö6976 requires late event(s) in
the melanoma progression. Since a strong increase in the
expression of the Gö6976-target « PKD1 » is observed in
M2 metastatic cells in comparison to their corresponding
primary tumor cells (I5), overexpression of this serine/
threonine kinase could be one of these events.
In contrast to Gö6976, the PKC inhibitor Gö6983 did
not affect any of the E-/N-cadherin expression, inter-
cellular interactions, β-catenin subcellular localization
or anchorage-independent growth in metastatic melan-
oma cells. Although Gö6983 could significantly inhibit
the chemotactic (FBS attraction in transwell) migration
of these cells but not their horizontal (wound healing)
migration, its effect was much lower than the effect of
Gö6976. These results suggest that suppression of spe-
cific PKC isoforms inhibited by Gö6976 but not by
Gö6983 would be involved in the reversion of the E- to
N-cadherin switch and metastatic phenotype in melan-
oma. Very few studies have attempted to examine the
involvement of PKCs in EMT, E/N-cadherin expression
regulation and/or cell-cell junctions. To our knowledge,
these studies were based on the treatment of the cells
with either PKC activator, phorbol ester [28, 49], or
PKC inhibitor Gö6976 [29, 50] but not on direct analysis
of the role of specific PKC isoforms. In fact, phorbol ester
has been shown to induce N-cadherin expression in osteo-
blasts [28] and EMT in prostate cancer [49]. On the other
hand, Gö6976 has been shown to promote formation of
cell junctions and inhibit invasion of urinary bladder car-
cinoma cells [29], suppress S252W FGFR-2 mutation-
induced N-cadherin expression in human osteoblasts [50]
and inhibit EMT in renal tubular epithelial cells [51].
These studies support our present data and indicate that
phorbol ester and Gö6976 targets, i.e. PKCs, can be in-
volved in the E- to N-cadherin switch; however, no spe-
cific isoforms could be determined as key players in this
process. A recently published study by Jain and Basu 2014
shows, by overexpression or siRNA techniques, that PKCε
promotes EMT in breast cancer [52]. However, this
isoform can’t be involved in the reversion of the E- to N-
cadherin switch observed in our present study because
neither Gö6976 nor Gö6983 is a potent inhibitor of PKCε,
which implies that, in melanoma cells, other PKC iso-
form(s) regulate the cadherin switch.
Given the differential effect of the PKC inhibitors
Gö6976 and Gö6983, our present data suggest that spe-
cific isoenzyme(s) targeted by Gö6976 but not by Gö6983
would be involved in the reversion of the E- to N-
cadherin switch and metastatic phenotype in melanoma.
In vitro kinase assays using recombinant full-length
PKC isoenzymes α, β, γ, δ, ε, ζ and μ (i.e. PKD1) show that
Gö6976 selectively inhibits PKCα (IC50 = 2.3 nM), PKCβ
(IC50 = 6.2 nM) and PKCμ (IC50 = 20 nM). However, it
does not affect the kinase activity of the PKCγ, δ, ε, and ζ-
isozymes even at μM levels [27]. On the other hand,
Gö6983 efficiently inhibits several PKC isozymes (IC50 = 7
nM for PKCα and PKCβ; 6 nM for PKCγ, 10 nM for PKCδ
and 60 nM for PKCζ) but is extremely inefficient in sup-
pressing PKCμ kinase activity in vitro (IC50 = 20 μM) [26].
Despite the highly conserved catalytic region of the
PKC isoforms, these kinases are differentially targeted
by Gö6976 and Gö6983 ATP-competitive inhibitors.
That can be due to variability in their regulatory region
that might affect the binding of the inhibitor to the kin-
ase domain [53]. Furthermore, although the chemical
structures of Gö6976 and Gö6983 are very close, the
central aromatic ring is opened in Gö6983 but intact in
Gö6976, which accounts for the different substrate
specificities of these inhibitors [26]. In contrast to the
other PKC isoforms that are not inhibited by Gö6976,
conventional PKCs (PKCα and PKCβ) and PKCμ share
tandem repetition of C1 motifs (forming the DAG/
PMA-binding domain) that is located at a comparable
distance towards the catalytic domain [23], which could
be important for the binding of Gö6976. On the other
hand, PKCμ significantly differs in some structural fea-
tures from the other PKC isoforms including PKCα and
PKCβ [23]. In fact, PKCμ is larger than the other PKCs
with a sequence of 912 amino acids. It contains a
hydrophobic domain in the N-terminal region and a
pleckstrin homology domain that are absent in the
other PKC isoforms. This additional sequence may be
responsible for the failure of Gö6983 to inhibit PKCμ
probably by preventing its binding to the ATP-binding
site. Furthermore, the specificity of action of these in-
hibitors can be independent of the regulatory domain
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of the PKCs but differences in small sequences or single
amino acids in their catalytic domains can affect the af-
finity of the inhibitors to the ATP-binding site. How-
ever, structural/molecular biology studies are required
determine the exact reason for the differences in
pharmacological action of these inhibitors.
Whatever the mechanism, since Gö6976 is a selective
inhibitor of PKCα, PKCβ and PKCμ and Gö6983 a select-
ive inhibitor of PKCα and PKCβ but not PKCμ [26, 27],
we hypothesized that the specific inhibition of PKCμ,
which is also known as PKD1, would be responsible for
the Gö6976-induced N- to E-cadherin switch and tumor
reversion in metastatic melanoma cells. Although this
serine/threonine kinase is a major cellular target for the
tumor-promoting phorbol esters and growth factors
which rapidly induce its activity [25, 54], PKD1 has a com-
plex relationship with respect to cancer development. In
fact, depending on the tissue type, PKD1 exerts different
functions and effects [55]. To date, the role of PKD1 in
melanoma initiation and progression is not yet explored,
except for the unique data by Kempkes et al. 2012 show-
ing that PKD1 knockdown inhibits proliferation and
migration-related processes such as filopodia formation
and αvβ3 integrin recycling in WM9 melanoma cell line
[56]. These data support our hypothesis. To study more
specifically and deeply the involvement of PKD1 in melan-
oma progression, we firstly analyzed the expression pat-
tern of this kinase in different melanoma cell lines. PKD1
was expressed in 4 out of the 5 melanoma cell lines tested
and this expression strongly correlated with E-cadherin
negative/N-cadherin positive phenotype and metastatic
potential (anchorage-independent growth and migration).
PKD1 knockdown in M4T2 metastatic melanoma cells
significantly induced down-regulation of N-cadherin and
up-regulation of E-cadherin (Additional file 4), supporting
the role of PKD1 in E-cadherin to N-cadherin switch.
Several studies suggest a role of PKD1 in gene expression
regulation either by direct interaction and phosphoryl-
ation of transcription factors [57, 58] or by phosphoryl-
ation and nuclear exclusion of histone deacetylases
(HDACs) [59]. Some of the transcription factors that can
be regulated by PKD1 are known to modulate the ex-
pression of E-cadherin or N-cadherin even if no direct
correlation between PKD1 and these cadherins has
been established. In fact, a study by Eiseler et al. 2012
has shown that PKD1 efficiently interacts in nuclei with
Snail1, the main transcription factor that suppresses E-
cadherin expression during EMT in most epithelial
cancers including melanoma [60, 61]. PKD1 phosphory-
lates Snail1 at Ser-11 which recruits HDAC-1 and −2 as
well as LOXL3, a transcriptional co-activator which is
also upregulated by PKD1. This newly formed complex
enhances Snail activity and induces proliferation and
anchorage-independent growth [57]. Although, in this
study, authors did not test whether this PKD1-mediated
regulation of snail1 activity might affect E-cadherin/N-
cadherin expression, another study by Peinado et al. 2004
shows that snail mediates E-cadherin repression by the re-
cruitment of HDAC1/2. Thus, it is very likely that PKD1
might inhibit E-cadherin expression using this mechan-
ism. On the other hand, PKD1 can induce the activation
of NFκB [62], a transcription factor that can directly bind
to N-cadherin promoter and activate its expression [63].
Interestingly, N-cadherin can also be directly regulated by
E-cadherin. In fact, loss of E-cadherin induces NFκB activ-
ity and consequent N-cadherin expression in melanoma
cells. Thus, regulation of E-cadherin expression by PKD1
could be enough to induce E- to N-cadherin switch.
Although a bunch of evidence suggest a role of PKD1 in
the regulation of transcription factors that are regulators
of E- or N-cadherin expression, these hypotheses need to
be tested to determine the exact mechanism by which
PKD1 regulates E- to N-cadherin switch.
In the second metastatic melanoma cell line tested
(i.e. M2), although the stable knockdown of PKD1 by
specific shRNAs induced the expression of E-cadherin,
these shPKD1-induced E-cadherin molecules could
only be detected as cleaved form in the colony spheres
of cells cultured in semi-solid medium or as secreted
molecules in the conditioned medium of the adherent
cells. Furthermore, the shPKD1-induced E-cadherin mole-
cules did not allow the formation of cell-cell junctions in
M2 melanoma cells; on the contrary, the cells transduced
by shPKD1 maintained their elongated mesenchymal and
isolated shape. Furthermore, although PKD1 knockdown
induced a slight decrease in the horizontal migration
(wound healing) potential of metastatic melanoma cells,
the inhibition was very low in comparison of the effect of
the Gö6976 inhibitor. These data suggest that the E-
cadherin molecules induced by PKD1 knockdown are not
functional, which is not surprising since these molecules
were observed in a truncated form. This observation could
be explained by the strong expression, by M2 melanoma
cells, of metalloproteinases (MMPs) such as MMP2,
MMP9, MMP12 and MMP13 [64–67] that may cleave the
newly synthesized E-cadherin molecules [68]. Noteworthy,
PKCs, in particular PKCα, have been shown to induce
MMP expression and/or activity [69–71]. Thus, the res-
toration of full length and functional E-cadherin mole-
cules by Gö6976 could be the consequence of the dual
inhibition of PKD1 (which induces E-cadherin expression)
and PKCα (which may inhibit expression and/or activ-
ity of MMPs, thus preventing the cleavage of the newly
synthesized E-cadherin). The mechanism by which E-
cadherin cleavage is mediated in M2 cells might be
absent or negatively regulated in M4T2 cells where full-
length E-cadherin could be detected after PKD1 knock-
down (Additional file 4). Thus, protease profiling and
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PKC isoform combination silencing experiments would
allow the verification of these hypotheses.
Finally, despite its failure to induce the expression of
functional E-cadherin, PKD1 knockdown alone strongly
altered anchorage-independent growth and migration of
metastatic melanoma cells, probably by regulating sig-
naling pathways such as extracellular signal-regulated
kinase (ERK), c-jun N-terminal kinase (JNK) and nuclear
factor-kappa B (NFκB), as previously described in
hormone-positive breast cancer [72, 73] and pancreatic
cancer [74, 75].
Conclusions
The cPKC/PKCμ inhibitor Gö6976 reverses the E- to N-
cadherin switch and as a consequence induces profound
morphological, molecular and cellular changes that re-
vert the mesenchymal phenotype and metastatic poten-
tial of aggressive melanoma cells. On the other hand, the
cPKC inhibitor Gö6983 doesn’t show any significant ef-
fect on this cadherin switch. The comparison of the tar-
get spectrum of these two PKC inhibitors indicates that
these observations are not the consequence of the inhib-
ition of cPKCs, but identifies a novel serine/threonine
kinase, i.e. PKCμ isoform (also known as PKD1), whose
specific inhibition by shRNAs induces E-cadherin ex-
pression and reverses the metastatic phenotype in all
metastatic melanoma cell lines tested. Noteworthy, in
one of these cell lines, specific inhibition of PKD1 alone
induces the expression of E-cadherin molecules which
are found to be cleaved, probably due to the effect of
proteases secreted by these cells. However, the PKD1/
cPKC inhibitor Gö6976 induces the expression of full
length E-cadherin in this same cell line. Thus, in some
melanoma cells, depending on their protease expression
profile, a combinatory inhibition of PKD1 and cPKC
might be considered for a more effective reversion of the
E- to N-cadherin switch.
Despite the recent advances in metastatic melanoma
treatments including molecular targeted and immune ther-
apies, many patients develop resistance or do not respond
to these therapeutic approaches. Since the E- to N-
cadherin switch plays a critical role in the response to these
therapies and in melanoma progression and based on our
data from the present study, we propose the inhibition of
PKD1 as a novel attractive approach for the treatment of
metastatic melanoma that should be further tested in pre-
clinical studies either alone or in combination with other
therapies depending of the disease context.
Additional files
Additional file 1: Correlation between N-/E-cadherin expression and
mesenchymal features in primary (T1 and I5) and metastatic (G1, M2 and
M4T2) melanoma cells. The relationship between N-cadherin (A) or E-
cadherin (B) expression and mesenchymal features in melanoma cells
was estimated using Pearson’s correlation analysis applied on the data
from western blot, MTT, methylcellulose and wound healing assays that
are presented in Figs. 1, 6 and 7a. In panel B, the last column of the table
represents the same correlation study but excluding I5 cell line from the
analysis. The results highlight the strong and significant negative correl-
ation between E-cadherin expression and mesenchymal features in most
melanoma models and the existence of some models (such as I5) in
which E-cadherin loss might not be enough to induce mesenchymal
features and might require additional events in tumor development.
(PPTX 64 kb)
Additional file 2: Effect of Gö6976 on the expression of E- and N-
cadherins and the anchorage-independent growth in I5 primary melan-
oma cell line. A. I5 primary melanoma cells were seeded in 6-well plates
at the density of 50,000 cells per well. After three days of culture, cells
were treated with 1 μM Gö6976, 1 μM Gö6983 or DMSO for 24 h. Cells
were then lysed and proteins analyzed by western blot using anti-E-
cadherin, anti-N-cadherin or anti-actin antibodies. T1 melanoma cells
were used as positive control for E-cadherin expression. B. I5 primary
melanoma cells were seeded in methylcellulose (1000 cells per plate)
containing 1 μM Gö6976 or 1 μM Gö6983. The colonies were
counted after 18 days of culture. (PPTX 135 kb)
Additional file 3: Correlation between PKD1 expression and
mesenchymal features in primary (T1 and I5) and metastatic (G1, M2 and
M4T2) melanoma cells. The relationship between PKD1 expression and
mesenchymal features in melanoma cells was estimated using Pearson’s
correlation analysis applied on the data from western blot, MTT,
methylcellulose and wound healing assays that are presented in Figs. 1, 6
and 7a. (PPTX 51 kb)
Additional file 4: PKD1 knockdown induces the expression of E-
cadherin and inhibits the expression of N-cadherin in M4T2 metastatic
melanoma cells. M4T2 cells were transfected or not with either specific
PKD1-targeting (siPKD1) or control non-targeting (siControl) siRNAs
according to the manufacturer protocol (Santa Cruz Biotechnology, sc-
36245 and sc-37007, respectively). Three days after transfection, these
cells were analyzed by western blot for PKD1, E-cadherin, N-cadherin
and actin expression. (PPTX 102 kb)
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